Responses of cultured human keratocytes and myofibroblasts to ethyl pyruvate: A microarray analysis of gene expression

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 6, 2010, Pages 2917-2927

  Harvey, Stephen A K ^a   Guerriero, Emily ^a   Charukamnoetkanok, Nahthai ^a   Piluek, Jordan ^a   Schuman, Joel S ^a   Sundarraj, Nirmala ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; KI 67 ANTIGEN; NFE2L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA CELL; DRUG EFFECT; DRUG RESPONSE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MYOFIBROBLAST; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION; CELL CULTURE; CELL LINE; CORNEA STROMA; CYTOLOGY; DNA MICROARRAY; FIBROBLAST; GENE; GENE EXPRESSION; GENETICS; METABOLISM; PHYSIOLOGY; WOUND HEALING;

CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELLS, CULTURED; CORNEAL STROMA; FIBROBLASTS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, CDC; HUMANS; KI-67 ANTIGEN; NF-E2-RELATED FACTOR 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PYRUVATES; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; WOUND HEALING;

EID: 77953252880     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4498     Document Type: Article

References (62)

1. Brand K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr. 1997;29:355-364.
2. O'Donnell-Tormey J, Nathan CF, Lanks K, DeBoer CJ, de la Harpe J. Secretion of pyruvate: an antioxidant defense of mammalian cells. J Exp Med. 1987;165:500-514.
3. Fink MP. Ethyl pyruvate. Curr Opin Anaesthesiol. 2008;21:160-167.
4. Varma SD, Devamanoharan PS, Ali AH. Prevention of intracellular oxidative stress to lens by pyruvate and its ester. Free Radic Res. 1998;28:131-135.
5. Varma SD, Hegde KR, Kovtun S. Oxidative damage to lens in culture: reversibility by pyruvate and ethyl pyruvate. Ophthalmologica. 2006;220:52-57.
6. Devamanoharan PS, Henein M, Ali AH, Varma SD. Attenuation of sugar cataract by ethyl pyruvate. Mol Cell Biochem. 1999;200:103-109.
7. Han Y, Englert JA, Yang R, Delude RL, Fink MP. Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther. 2005;312:1097-1105.
8. Pasquale LR, Dorman-Pease ME, Lutty GA, Quigley HA, Jampel HD. Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci. 1993;34:23-30.
9. Matsuda A, Tagawa Y, Matsuda H. TGF-beta2, tenascin, and integrin beta1 expression in superior limbic keratoconjunctivitis. Jpn J Ophthalmol. 1999;43:251-256.
10. Thom SB, Myers JS, Rapuano CJ, Eagle RC Jr, Siepser SB, Gomes JA. Effect of topical anti-transforming growth factor-beta on corneal stromal haze after photorefractive keratectomy in rabbits. J Cataract Refract Surg. 1997;23:1324-1330.
11. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative antiscarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-3401.
12. Mita T, Yamashita H, Kaji Y, et al. Effects of transforming growth factor beta on corneal epithelial and stromal cell function in a rat wound healing model after excimer laser keratectomy. Graefes Arch Clin Exp Ophthalmol. 1998;236:834-843.
13. Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions in the cornea. Prog Retin Eye Res. 1999;18:293-309.
14. Wilson SE, Lloyd SA, He YG. EGF, basic FGF, and TGF beta-1 messenger RNA production in rabbit corneal epithelial cells. Invest Ophthalmol Vis Sci. 1992;33:1987-1995.
15. Maltseva O, Folger P, Zekaria D, Petridou S, Masur SK. Fibroblast growth factor reversal of the corneal myofibroblast phenotype. Invest Ophthalmol Vis Sci. 2001;42:2490-2495.
16. Li DQ, Lee SB, Tseng SC. Differential expression and regulation of TGF-beta1, TGF-beta2, TGF-beta3, TGF-betaRI, TGF-betaRII and TGF-betaRIII in cultured human corneal, limbal, and conjunctival fibroblasts. Curr Eye Res. 1999;19:154-161.
17. Song QH, Klepeis VE, Nugent MA, Trinkaus-Randall V. TGF-beta1 regulates TGF-beta1 and FGF-2 mRNA expression during fibroblast wound healing. Mol Pathol. 2002;55:164-176.
18. Petridou S, Maltseva O, Spanakis S, Masur SK. TGF-beta receptor expression and smad2 localization are cell density dependent in fibroblasts. Invest Ophthalmol Vis Sci. 2000;41:89-95.
19. Petridou S, Masur SK. Immunodetection of connexins and cadherins in corneal fibroblasts and myofibroblasts. Invest Ophthalmol Vis Sci. 1996;37:1740-1748.
20. Guerriero E, Chen J, Sado Y, et al. Loss of alpha3(IV) collagen expression associated with corneal keratocyte activation. Invest Ophthalmol Vis Sci. 2007;48:627-635.
21. Anderson SC, SundarRaj N. Regulation of a Rho-associated kinase expression during the corneal epithelial cell cycle. Invest Ophthalmol Vis Sci. 2001;42:933-940.
22. Harvey SA, Anderson SC, SundarRaj N. Downstream effects of ROCK signaling in cultured human corneal stromal cells: microarray analysis of gene expression. Invest Ophthalmol Vis Sci. 2004; 45:2168-2176.
23. Funderburgh JL, Funderburgh ML, Mann MM, Conrad GW. Physical and biological properties of keratan sulphate proteoglycan. Biochem Soc Trans. 1991;19:871-876.
24. Beales MP, Funderburgh JL, Jester JV, Hassell JR. Proteoglycan synthesis by bovine keratocytes and corneal fibroblasts: maintenance of the keratocyte phenotype in culture. Invest Ophthalmol Vis Sci. 1999;40:1658-1663.
25. Funderburgh JL, Funderburgh ML, Mann MM, Corpuz L, Roth MR. Proteoglycan expression during transforming growth factor betainduced keratocyte-myofibroblast transdifferentiation. J Biol Chem. 2001;276:44173-44178.
26. Carlson EC, Wang IJ, Liu CY, Brannan P, Kao CW, Kao WW. Altered KSPG expression by keratocytes following corneal injury. Mol Vis. 2003;9:615-623.
27. Chen J, Guerriero E, Sado Y, SundarRaj N. Rho-mediated regulation of TGF-beta1- and FGF-2-induced activation of corneal stromal keratocytes. Invest Ophthalmol Vis Sci. 2009;50:3662-3670.
28. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899-2908.
29. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
30. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell. 1993;75:805-816.
31. Chen W, Sun Z, Wang XJ, et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009;34:663-673.
32. Smith ML, Seo YR. p53 regulation of DNA excision repair pathways. Mutagenesis. 2002;17:149-156.
33. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet. 2003; 34:440-445.
34. Liu X, Xue L, Yen Y. Redox property of ribonucleotide reductase small subunit M2 and p53R2. Methods Mol Biol. 2008;477:195-206.
35. Cano CE, Gommeaux J, Pietri S, et al. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res. 2009;69:219-226.
36. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107-120.
37. Mizuno H, Nakanishi Y, Ishii N, Sarai A, Kitada K. A signature-based method for indexing cell cycle phase distribution from microarray profiles. BMC Genomics. 2009;10:137.
38. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803-1815.
39. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291-13295.
40. Dhakshinamoorthy S, Jaiswal AK. C-Maf negatively regulates AREmediated detoxifying enzyme genes expression and anti-oxidant induction. Oncogene. 2002;21:5301-5312.
41. Blank V. Small Maf proteins in mammalian gene control: mere dimerization partners or dynamic transcriptional regulators? J Mol Biol. 2008;376:913-925.
42. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, Yamamoto M. Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol. 2005;25:8044-8051.
43. Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, Hardingham GE. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells. 2009;27:279-282.
44. Rhee SG, Jeong W, Chang TS, Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl. 2007;S3-S8.
45. Wilson SE, Mohan RR, Netto M, et al. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. Invest Ophthalmol Vis Sci. 2004;45:2201-2211.
46. Wilson SE, Li Q, Weng J, et al. The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci. 1996;37:1582-1592.
47. Pei Y, Reins RY, McDermott AM. Aldehyde dehydrogenase (ALDH) 3A1 expression by the human keratocyte and its repair phenotypes. Exp Eye Res. 2006;83:1063-1073.
48. Estey T, Cantore M, Weston PA, Carpenter JF, Petrash JM, Vasiliou V. Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. J Biol Chem. 2007;282:4382-4392.
49. Stagos D, Chen Y, Cantore M, Jester JV, Vasiliou V. Corneal aldehyde dehydrogenases: multiple functions and novel nuclear localization. Brain Res Bull. 2010;15;81:211-218.
50. Niakan KK, McCabe ER. DAX1 origin, function, and novel role. Mol Genet Metab. 2005;86:70-83.
51. Zieske JD, Takahashi H, Hutcheon AE, Dalbone AC. Activation of epidermal growth factor receptor during corneal epithelial migration. Invest Ophthalmol Vis Sci. 2000;41:1346-1355.
52. Block ER, Matela AR, SundarRaj N, Iszkula ER, Klarlund JK. Wounding induces motility in sheets of corneal epithelial cells through loss of spatial constraints: role of heparin-binding epidermal growth factorlike growth factor signaling. J Biol Chem. 2004;279:24307-24312.
53. Bek EL, McMillen MA. Endothelins are angiogenic. J Cardiovasc Pharmacol. 2000;36:S135-S139.
54. Osada M, Park HL, Park MJ, et al. A p53-type response element in the GDF15 promoter confers high specificity for p53 activation. Biochem Biophys Res Commun. 2007;354:913-918.
55. Kempf T, Eden M, Strelau J, et al. The transforming growth factorbeta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98:351-360.
56. Badea T, Niculescu F, Soane L, et al. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into Sphase. J Biol Chem. 2002;277:502-508.
57. Fosbrink M, Cudrici C, Niculescu F, et al. Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol. 2005; 78:116-122.
58. Saigusa K, Imoto I, Tanikawa C, et al. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene. 2007;26:1110-1121.
59. Manda R, Kohno T, Matsuno Y, Takenoshita S, Kuwano H, Yokota J. Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. Genomics. 1999;61:5-14.
60. Matusiak D, Glover S, Nathaniel R, Matkowskyj K, Yang J, Benya RV. Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. Am J Physiol Gastrointest Liver Physiol. 2005;288:G718-G728.
61. Siegfried JM, Krishnamachary N, Gaither Davis A, Gubish C, Hunt JD, Shriver SP. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther. 1999;12:291-302.
62. Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cell Signal. 2008;20:269-276.